Collegeville, PA, United States of America

Millard Hurst Lambert, Iii


Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Millard Hurst Lambert, III

Introduction

Millard Hurst Lambert, III, located in Collegeville, PA, is a prominent inventor with a focus on innovative pharmacological solutions. With a notable, singular patent to his name, Lambert's work in the field of medicinal chemistry has garnered attention for its potential therapeutic applications.

Latest Patents

Mr. Lambert holds a patent for “MrgX2 antagonists.” This invention encompasses novel compounds formulated according to specific structural criteria which act as antagonists of MrgX2. Additionally, the patent covers pharmaceutical compositions containing these compounds, as well as their utility in treating diseases and disorders associated with MrgX2 mediation.

Career Highlights

Currently, Millard Hurst Lambert, III is associated with GlaxoSmithKline Intellectual Property Development Limited, a globally recognized leader in pharmaceutical innovation. His role at this esteemed company allows him to contribute significantly to the advancement of therapeutic solutions based on his groundbreaking research.

Collaborations

Throughout his career, Lambert has likely engaged in collaborations with various research institutions and professionals within the pharmaceutical industry. Such partnerships are crucial in furthering research and development processes, enhancing the impact of his inventions on patient care.

Conclusion

Millard Hurst Lambert, III exemplifies the spirit of innovation within the pharmaceutical sector. His contributions through patents like the MrgX2 antagonists propel forward the quest for effective therapies, showcasing the continual progress being made in the treatment of complex diseases. His work not only benefits the industry but also represents a significant stride towards improving patient health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…